People Background Check
Find People:

Peter E Besmer, Age 8421 Spencer Ave, Guilford, CT 06437

Get Report
Known as:
Besmer Besmer
Related to:
Bruce M Bicknell 93 Barbara A Robinson 63

Peter Besmer Phones & Addresses

21 Spencer Ave, Guilford, CT 06437 (203) 453-8797

500 83Rd St, New York, NY 10028 (212) 570-2314

21 Spencer Ave, Guilford, CT 06437 (203) 240-0482

Mentions for Peter E Besmer

Peter Besmer resumes & CV records

Resumes

Peter Besmer Photo 3

Member At Memorial Sloan-Kettering Cancer Center

Location:
1275 York Ave, New York, NY 10065
Industry:
Hospital & Health Care
Work:
Memorial Sloan Kettering Cancer Center
Member at Memorial Sloan-Kettering Cancer Center
Peter Besmer Photo 4

Member And Professor

Location:
Guilford, CT
Industry:
Hospital & Health Care
Work:
Memorial Sloan Kettering Cancer Center
Member and Professor
Languages:
German

Publications & IP owners

Us Patents

C-Kit Ligand-Based Method For Expanding Peripheral Blood Cell Levels

US Patent:
6403559, Jun 11, 2002
Filed:
Aug 10, 1999
Appl. No.:
09/371261
Inventors:
Peter Besmer - New York NY
Jochen Buck - New York NY
Malcolm A. S. Moore - New York NY
Karl Nocka - Harvard MA
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A61K 3804
US Classification:
514 12, 514 2, 424 851, 530350, 530351
Abstract:
A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.

Ligand For The C-Kit Receptor And Methods Of Use Thereof

US Patent:
2003010, Jun 5, 2003
Filed:
Apr 24, 2002
Appl. No.:
10/132345
Inventors:
Peter Besmer - New York NY, US
Jochen Buck - New York NY, US
Malcolm Moore - New York NY, US
Karl Nocka - Harvard MA, US
Assignee:
Sloan-Kettering Institute For Cancer Research
International Classification:
A61K038/20
US Classification:
424/085200, 514/012000
Abstract:
A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.

Ligand For The C-Kit Receptor And Methods Of Use Thereof

US Patent:
2003012, Jul 3, 2003
Filed:
Oct 5, 1990
Appl. No.:
07/594306
Inventors:
PETER BESMER - NEW YORK NY, US
KARL NOCKA - LEONIA NJ, US
JOCHEN BUCK - NEW YORK NY, US
International Classification:
A01N037/18
A61K038/00
C12N015/87
C12P021/06
C07K001/00
C07K014/00
C07K017/00
C12N015/63
C12N015/85
US Classification:
530/350000, 514/002000
Abstract:
This invention provides an isolated nucleic acid molecule which encodes an amino acid sequence corresponding to a c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof. A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods and a pharmaceutically acceptable carrier is further provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention.

Ligand For The C-Kit Receptor And Methods Of Use Thereof

US Patent:
2005027, Dec 15, 2005
Filed:
Nov 12, 2004
Appl. No.:
10/988476
Inventors:
Peter Besmer - New York NY, US
Jochen Buck - Old Greenwich CT, US
Malcolm Moore - New York NY, US
Karl Nocka - Harvard MA, US
International Classification:
A61K038/19
A61K038/20
US Classification:
424085100, 424085200
Abstract:
A pharmaceutical composition which comprises the c- ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c- ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.

Ligand For The C-Kit Receptor And Methods Of Use Thereof

US Patent:
2008015, Jun 26, 2008
Filed:
Aug 3, 2007
Appl. No.:
11/890212
Inventors:
Peter Besmer - New York NY, US
Jochen Buck - Old Greenwich CT, US
Malcolm A.S. Moore - New York NY, US
Karl Nocka - Harvard MA, US
International Classification:
A61K 39/395
A61P 35/00
US Classification:
4241411, 4241301
Abstract:
A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.

Compositions Of Soluble C-Kit Ligand And Hematopoietic Factors

US Patent:
5767074, Jun 16, 1998
Filed:
Nov 17, 1994
Appl. No.:
8/341456
Inventors:
Peter Besmer - New York NY
Jochen Buck - New York NY
Malcolm A.S. Moore - New York NY
Karl Nocka - Harvard MA
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A61K 3804
A61K 3819
C07K 14435
C07K 1452
US Classification:
514 12
Abstract:
A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described.

Use Of C-Kit Ligand With Tnf-.Alpha. And Hematopoietic Factors For The Expansion Or Differentiation Of Hematopoietic Cells

US Patent:
6159461, Dec 12, 2000
Filed:
Jul 23, 1997
Appl. No.:
8/898982
Inventors:
Peter Besmer - New York NY
Jochen Buck - New York NY
Malcolm A. S. Moore - New York NY
Karl Nocka - Harvard MA
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A61K 3818
A61K 3819
A61K 3820
US Classification:
424 851
Abstract:
Compositions comprising c-kit ligand, TNF-. alpha. , and a hematopoietic factor are useful to promote the expansion of peripheral blood cells or the expansion and differentiation of hematopoietic progenitor cells.

Method For Increasing The Level Of Stem Cells In Peripheral Blood

US Patent:
5935565, Aug 10, 1999
Filed:
Jun 7, 1995
Appl. No.:
8/478414
Inventors:
Peter Besmer - New York NY
Jochen Buck - New York NY
Malcolm A. S. Moore - New York NY
Karl Nocka - Harvard MA
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A61K 4505
A61K 3700
US Classification:
424 851
Abstract:
A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described.

Possible Relatives

Fremont T Besmer  Peter D Stamps  Peter J Standish  Peter G Johnston  Peter D Jones  Peter Y Stangl  Peter W Stanislaw  Peter A Stannard  Peter B Stanton  Peter Stark 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.